It is a new day for cancer research and for cancer patients. Rapidly evolving technology is enabling extraordinary advances in cancer research that deepen our understanding of how cancer develops, grows and threatens the lives of millions. By exploiting this growing body of knowledge about cancer biology, we can be more strategic and innovative than ever before in the way we attack cancer. This is quickening the pace of developing new ways to prevent, detect, diagnose and treat cancer.The AACR Cancer Progress Report 2012 celebrates the many ways that we have made research count for cancer patients, particularly in the past year alone. Decades of research, in large part thanks to our Nation's long-standing investment in cancer research and biomedical science by the National Institutes of Health (NIH) and the National Cancer Institute (NCI), have provided the foundation for the progress that is helping usher in this new day for patients with many forms of cancer.Highlighted in this Report are treatment advances approved by the U.S. Food and Drug Administration (FDA) in the past 12 months alone, including: 1) a new drug for treating precancerous lesions of the skin; 2) eight new drugs for treating a variety of types of cancer, of which two are entirely new classes of drugs; 3) four new uses for previously approved cancer drugs, one of the four uses being an alternative administration to reduce side effects. The Report also presents new discoveries that are forming the foundation of tomorrow's progress.As a reminder of why it is so critical for the Nation to prioritize cancer research and biomedical science, the 2012 Report describes the exciting research progress and scientific opportunities ahead. Also, to put a face on the realities of cancer, we have chronicled the experiences and the sentiments of twelve cancer survivors, and as well as a mother and father who suffered unimaginable grief when their seven-year-old child died of neuroblastoma.
Source: AACR Cancer Progress Report 2012. AACR Cancer Progress Report Writing Committee. Clin Cancer Res. 2012 Sep 11.
Free paper available at: